UroGen Pharma (NASDAQ:URGN - Get Free Report) had its target price raised by investment analysts at Guggenheim from $15.00 to $30.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's target price would suggest a potential upside of 149.38% from the company's previous close.
A number of other research analysts have also issued reports on the company. HC Wainwright lowered UroGen Pharma from a "buy" rating to a "neutral" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group reduced their price target on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday. Oppenheimer reduced their price target on UroGen Pharma from $36.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, June 3rd. Finally, Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $28.71.
Read Our Latest Stock Report on URGN
UroGen Pharma Stock Performance
NASDAQ:URGN traded up $0.95 during midday trading on Friday, reaching $12.03. 19,618,047 shares of the company traded hands, compared to its average volume of 991,666. UroGen Pharma has a twelve month low of $3.42 and a twelve month high of $20.70. The firm has a market capitalization of $554.67 million, a price-to-earnings ratio of -3.82 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a fifty day moving average price of $8.49 and a 200 day moving average price of $10.07.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. On average, analysts expect that UroGen Pharma will post -3.12 EPS for the current fiscal year.
Insider Activity at UroGen Pharma
In related news, insider Mark Schoenberg sold 5,162 shares of UroGen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the transaction, the insider now directly owns 153,378 shares of the company's stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.10% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC grew its holdings in UroGen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after acquiring an additional 24,839 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of UroGen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the period. Parkman Healthcare Partners LLC boosted its position in shares of UroGen Pharma by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock valued at $4,348,000 after purchasing an additional 23,292 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of UroGen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock valued at $258,000 after purchasing an additional 1,653 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of UroGen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock valued at $1,262,000 after purchasing an additional 88,577 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.
About UroGen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
